

	M43 - ENOXAPARIN (LOVENOX)	
	Version date: 2025-02-16	Effective date: 2025-04-30 (07:00)
ERS HIGH ALERT MEDICATION (A03)		

INDICATIONS
<ul style="list-style-type: none"> Known or suspected ST elevation myocardial infarction (STEMI) if the patient is going directly to primary coronary intervention (PCI)

WARNINGS
ABSOLUTE CONTRAINDICATIONS: <ul style="list-style-type: none"> Hypersensitivity to enoxaparin Patient may be candidate for fibrinolysis Active major bleeding Heparin-induced thrombocytopenia (HIT) within the past 100 days
USE WITH CAUTION: <ul style="list-style-type: none"> Current anticoagulation use Renal impairment Heparin-induced thrombocytopenia greater than 100 days ago

ADMINISTRATION	
This requires authorization from the Code-STEMI physician / VECTRS emergency physician (or designate)	
INTRAVENOUS (INTRAOSSEOUS)	PCP / ICP / ACP
ADULTS UNDER 75 YEARS: <ul style="list-style-type: none"> Administer 0.5 mg/kg by slow push over 60 second Maximum per dose = 50 mg 	
SUBCUTANEOUS	PCP / ICP / ACP
ADULTS UNDER 75 YEARS: <ul style="list-style-type: none"> Administer 1 mg/kg Maximum per dose = 100 mg ADULTS OVER 75 YEARS: <ul style="list-style-type: none"> Administer 0.75 mg/kg Maximum per dose = 75 mg 	

NOTES
1. There is an increased risk of intracranial bleeding in patients over 75 years of age.

LINKS
<ul style="list-style-type: none"> • A03 - High Alert Medications • E04 - Acute Coronary Syndrome & STEMI & NSTEMI-ACS

APPROVED BY	
	
Provincial Medical Director	Provincial Associate Medical Director

VERSION CHANGES (refer to X08 for change tracking)
<ul style="list-style-type: none"> • Addition of advanced work scope • Revised contraindications / cautions